Artículos con órdenes de acceso público - Raymond ChungMás información
No disponibles en ningún lugar: 26
Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection
RC Hoogeveen, MP Robidoux, T Schwarz, L Heydmann, JA Cheney, ...
Gut 68 (5), 893-904, 2019
Órdenes: US National Institutes of Health, Royal Netherlands Academy of Arts and Sciences
Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment
J Chan, N Gogela, H Zheng, S Lammert, T Ajayi, Z Fricker, AY Kim, ...
Digestive diseases and sciences 63, 486-492, 2018
Órdenes: US National Institutes of Health
Acute liver injury and acute liver failure from mushroom poisoning in N orth A merica
CJ Karvellas, H Tillman, AA Leung, WM Lee, ML Schilsky, B Hameed, ...
Liver International 36 (7), 1043-1050, 2016
Órdenes: US National Institutes of Health
Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study
ED Bethea, K Gaj, JL Gustafson, A Axtell, T Lebeis, M Schoenike, ...
The lancet Gastroenterology & hepatology 4 (10), 771-780, 2019
Órdenes: US National Institutes of Health
Sofosbuvir‐based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES
AA Butt, P Yan, OS Shaikh, RT Chung, KE Sherman, ERCHIVES study
Liver International 36 (5), 651-658, 2016
Órdenes: US Department of Veterans Affairs
Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop
A Monto, RT Schooley, JC Lai, MS Sulkowski, RT Chung, JM Pawlotsky, ...
Official journal of the American College of Gastroenterology| ACG 105 (5 …, 2010
Órdenes: US National Institutes of Health
Dynamic changes in innate immune responses during direct‐acting antiviral therapy for HCV infection
JA Holmes, C Carlton‐Smith, AY Kim, EO Dumas, J Brown, JL Gustafson, ...
Journal of Viral Hepatitis 26 (3), 362-372, 2019
Órdenes: US National Institutes of Health
Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease: the potential role of ezetimibe
TG Simon, KE Corey, RT Chung, R Giugliano
Digestive diseases and sciences 61, 3425-3435, 2016
Órdenes: US National Institutes of Health
Entry inhibitors and future treatment of hepatitis C
I Fofana, N Jilg, RT Chung, TF Baumert
Antiviral research 104, 136-142, 2014
Órdenes: National Institute of Health and Medical Research, France, European Commission
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir‐based regimens: results from ERCHIVES
AA Butt, P Yan, OS Shaikh, RT Chung, KE Sherman, ERCHIVES study
Liver International 36 (9), 1275-1283, 2016
Órdenes: US Department of Veterans Affairs
Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients
ME Sise, DF Chute, JL Gustafson, D Wojciechowski, N Elias, RT Chung, ...
Hemodialysis International 22, S71-S80, 2018
Órdenes: US National Institutes of Health
Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy
R Rajbhandari, K Barton, AC Juncadella, AK Rubin, T Ajayi, Y Wu, ...
Journal of Viral Hepatitis 23 (7), 561-568, 2016
Órdenes: US National Institutes of Health
Reduced albumin dosing during large-volume paracentesis is not associated with adverse clinical outcomes
KB Johnson, JL Mueller, TG Simon, H Zheng, LY King, RS Makar, ...
Digestive Diseases and Sciences 60, 2190-2195, 2015
Órdenes: US National Institutes of Health
Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study
S Gawrieh, JE Lake, P Debroy, JA Sjoquist, M Robison, M Tann, F Akisik, ...
Hepatology 78 (2), 578-591, 2023
Órdenes: US National Institutes of Health
The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A …
P Huang, Y Wang, M Yue, Z Ge, X Xia, AJ Jeyarajan, JA Holmes, R Yu, ...
Liver International 41 (10), 2341-2357, 2021
Órdenes: US National Institutes of Health, National Natural Science Foundation of China
Changes in serum hepatitis B surface and e antigen, interferon‐inducible protein 10, and aminotransferase levels during combination therapy of immune‐tolerant chronic hepatitis B
R Perrillo, HHS Lin, KB Schwarz, P Rosenthal, M Lisker‐Melman, ...
Hepatology 76 (3), 775-787, 2022
Órdenes: US National Institutes of Health
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates
E Barnes, GS Cooke, GM Lauer, RT Chung
Hepatology 77 (5), 1757-1772, 2023
Órdenes: US National Institutes of Health, UK Medical Research Council, National …
Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorder
AGL Vannier, B Wardwell, V Fomin, A PeBenito, N Wolczynski, S Piaker, ...
Alcohol 95, 37-43, 2021
Órdenes: US National Institutes of Health
Current guidelines and prioritizing treatment of hepatitis C virus in HIV-infected patients
ER Feeney, RT Chung, Y Yazdanpanah
Current Opinion in HIV and AIDS 10 (5), 323-329, 2015
Órdenes: US National Institutes of Health
Clinical significance of quantitative e antigen in a cohort of hepatitis B virus‐infected children and adults in North America
SL Cooper, WC King, DB Mogul, MG Ghany, KB Schwarz, ...
Journal of Viral Hepatitis 28 (7), 1042-1056, 2021
Órdenes: US National Institutes of Health
La información de publicación y financiación se determina de forma automática mediante un programa informático